The British pharma giant said Emma Walmsley's current pay could put off candidates for her eventual successor.

For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. | For GSK CEO Emma Walmsley, ...

One of the lowest paid CEOs in pharma—and the only woman leading a top-tier giant—is set to receive up to $27.2 million in ...

UK drugmaker says Emma Walmsley is underpaid compared with global competitors as it abandons diversity targets ...

There is no escaping from the fact that the British company has proved perennially disappointing for investors. Around £10bn ...

GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...

While both broadly agreed with the company’s plans to spin off its consumer-health unit, they questioned whether Chief ...

British drugmaker GSK will no longer set diversity targets, it said on Thursday, as it became the latest company to scale ...

Almost half of councils in England risk falling into bankruptcy without action to address a £4.6bn deficit amassed under a ...

UK drugmaker GSK is struggling to convince the market that it can deliver on its plans to refill its pipeline ahead of a key patent expiry, as US hedge fund Citadel took the largest short position ...

The pharma giant has operated in Ireland for decades and continues to have operations in key locations such as Cork and ...

Dame Emma Walmsley Thanks Julie. so in summary, GSK is powering forward. This comes on the back of a strong track record of operational delivery and accelerating progress in innovation and ...